SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: mod who wrote (5953)1/26/1999 4:38:00 PM
From: Henry Niman  Respond to of 6136
 
WLA has been heading south lately because of Rezulin concerns (see Ligand Diabetes page at biocognizance.com for MANY links).



To: mod who wrote (5953)1/26/1999 4:42:00 PM
From: Steve Fancy  Read Replies (1) | Respond to of 6136
 
Dennis, could trade flat to up slightly as shorts cover. Assuming good earnings, a two point risk factor may be reasonable.

WLA CEO on squawk box tomorrow.

sf



To: mod who wrote (5953)1/26/1999 5:03:00 PM
From: Steve Fancy  Read Replies (1) | Respond to of 6136
 
Dennis, I wonder...is it possible this deal does not include the Oncology stock? Otherwise seems that AGPH must have felt they were pressing the extreme upper bounds of valuation to sell at 60.

Nah, guess the PRNewsire article shoots that theory.

sf


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News